Author: Aditya Pareek | EQMint | Press release

Symbiotec Pharmalab Limited, a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).

Symbiotec Pharmalab Limited plans to raise funds through offer of equity shares (face value ₹ 2 each) through initial public offerings aggregating up to ₹ 2,180 Crore. The offer comprises of fresh issue of equity shares aggregating up to ₹ 150 crore (The “Fresh Issue”) and offer for sale by Selling Shareholders aggregating up to ₹ 2,030 crore (The “Offer for Sale”).

Symbiotec Pharmalab Limited plans to utilise fund raised through net proceeds on a.) Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company and b.) General corporate purposes.

Symbiotec Pharmalab Limited has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs. (Source: F&S Report). It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of company’s portfolio. The company manufacture these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations.

The Equity Shares of Symbiotec Pharmalab Limited that will be offered through the Red Herring Prospectus are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”). JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers to the issue.

About The Company:

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across threeplatforms-organic chemistry, biotechnology and complex injectables. Symbiotec Pharmalab Limited has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs. (Source: F&S Report) It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of its portfolio. The Company manufacture these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, Symbiotec Pharmalab Limited has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. The Company has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (“CDMO”) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufacture its own products.

As of June 30, 2025, the Symbiotec Pharmalab Limited had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres (“KL”). Further, as of the date of this Draft Red Herring Prospectus, the company has newly commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum. Enabling it to function as a vertically integrated ‘microbe-to-pharmacy’ and ‘farm-to-pharmacy’ platform with cost-efficient operations. Symbiotec Pharmalab Limited’s biotechnology facilities are equipped with fermenters of 5 KL, 35 KL and 100 KL, providing us flexibility in the scale of its operations. Further, the company is in the process of expanding its biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing in Ujjain.

Disclaimer:

Symbiotec Pharmalab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated December 19, 2025 with the SEBI and the Stock Exchanges. The DRHP is available on the website of the Company at www.symbiotec.com, SEBI at www.sebi.gov.in, as well as on the websites of the BRLMs, i.e., JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited*and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfl.com, www.avendus.com, www.motilaloswalgroup.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively.

Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled “Risk Factors” on page 42 of the DRHP and the details set out in the Red Herring Prospectus, when filed. Any potential investors should not rely on the DRHP for making any investment decision. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act, and (b) outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made. *In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations, and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.

For more such updates visit EQMint